Automated online monitoring & control to improve processes and decision making in cell and gene therapy manufacturing
The project aims to develop an automated, self-contained bioreactor with continuous monitoring of critical process parameters to enhance scalability and quality in cell and gene therapy manufacturing.
Projectdetails
Problem
Cell and gene therapies (CGT) represent a breakthrough in the treatment of a wide range of conditions. However, limited global manufacturing capacity owing to a lack of scalability prevents CGT from becoming widely available to patients. Therapies are prepared individually at central facilities in a series of complex open manual steps.
Variability is high, and a uniform manufacturing process is lacking. Automated, standardized, quality-controlled, and decentralized processes are urgently needed to scale out CGT manufacturing, bring down costs, and enable treatment for millions of patients. True automation requires an understanding of what are known as critical process parameters (CPPs). Currently, manufacturing of cell therapies is carried out over several days, with limited access to knowledge of CPPs, often obtained through intrusive sampling methods.
Innovation
We aim to enable in-line continuous monitoring of key cell culture parameters during therapy manufacturing. To do this, we will create a self-contained instrument that connects miniaturized biosensor technologies to a novel bioreactor to allow automation of the entire cell therapy manufacturing process in a closed system.
The device will accommodate a disposable, single-use sampling unit that will ultimately be adaptable to any bioreactor. Our platform will carry out continuous, automated, and closed monitoring of a set of well-defined CPPs, as indicators of the overall state of the cell culture.
We will select and refine our parameters and establish optimal ranges as predictors of process outcomes and product quality, based on prediction algorithms and digital twin analysis. This will allow continuous process monitoring while greatly lowering costs and risks associated with manual sampling.
Our first application will be in CAR T cell therapy production, but the advantages of automation with continuous monitoring will be further applied to other CGT products that involve culturing of cells.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 3.617.783 |
Totale projectbegroting | € 3.617.783 |
Tijdlijn
Startdatum | 1-10-2022 |
Einddatum | 30-9-2025 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- DA VINCI LABSpenvoerder
- JOBST TECHNOLOGIES GMBH
- STEMMATTERS, BIOTECNOLOGIA E MEDICIINA REGENERATIVA SA
- TECHNISCHE UNIVERSITAET WIEN
- EXOTHERA SA
- CROWDHELIX LIMITED
- LIMULA SA
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation. | EIC Pathfinder | € 2.996.550 | 2022 | Details |
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images. | EIC Pathfinder | € 2.744.300 | 2022 | Details |
Dynamic Spatio-Temporal Modulation of Light by Phononic ArchitecturesDynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements. | EIC Pathfinder | € 2.552.277 | 2022 | Details |
Emerging technologies for crystal-based gamma-ray light sourcesTECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology. | EIC Pathfinder | € 2.643.187 | 2022 | Details |
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"
The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.
The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.
Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures
Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.
Emerging technologies for crystal-based gamma-ray light sources
TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Commercial feasibility of a cell-free reactor setup for optimisation of complex enzymatic pathwaysThis project aims to commercialize a continuous stirred tank reactor for optimizing complex enzymatic pathways, enhancing production efficiency and establishing a viable commercialization strategy. | ERC POC | € 150.000 | 2022 | Details |
Continuous Digitalized Processes for Producing BiopharmaceuticalsDeveloping a Digital Twin-based methodology for continuous, integrated biopharmaceutical production to enhance efficiency and support advanced therapies like mRNA vaccines and personalized medicine. | ERC ADG | € 2.500.000 | 2023 | Details |
Enabling efficient cell engineering leaving gene-expression BURden OUT for cell therapies and biopharmaceutical industryBURnOUT is an AI-driven software designed to optimize gene sequences for efficient mammalian cell engineering, aiming to reduce costs and enhance therapies for cancer and biopharmaceuticals. | ERC POC | € 150.000 | 2024 | Details |
Generation, validation and use of a synthetic reporter of CAR T cell products function and dysfunctionDevelop a synthetic reporter system to enhance T cell fitness in immunotherapy by identifying and reversing dysfunction in CAR T cells for improved cancer treatment. | ERC POC | € 150.000 | 2024 | Details |
Commercial feasibility of a cell-free reactor setup for optimisation of complex enzymatic pathways
This project aims to commercialize a continuous stirred tank reactor for optimizing complex enzymatic pathways, enhancing production efficiency and establishing a viable commercialization strategy.
Continuous Digitalized Processes for Producing Biopharmaceuticals
Developing a Digital Twin-based methodology for continuous, integrated biopharmaceutical production to enhance efficiency and support advanced therapies like mRNA vaccines and personalized medicine.
Enabling efficient cell engineering leaving gene-expression BURden OUT for cell therapies and biopharmaceutical industry
BURnOUT is an AI-driven software designed to optimize gene sequences for efficient mammalian cell engineering, aiming to reduce costs and enhance therapies for cancer and biopharmaceuticals.
Generation, validation and use of a synthetic reporter of CAR T cell products function and dysfunction
Develop a synthetic reporter system to enhance T cell fitness in immunotherapy by identifying and reversing dysfunction in CAR T cells for improved cancer treatment.